Product image of Jivolar (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Jivolar

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Jivolar (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride and Sitagliptin, the active ingredients in Jivolar, are a combined biguanide and DPP‑4 inhibitor presented as an oral tablet for oral use. They treat type 2 diabetes mellitus in adult patients by improving glycemic control. Metformin reduces hepatic glucose output while Sitagliptin enhances insulin secretion in a glucose‑dependent manner, together offering complementary mechanisms for blood sugar management.

GNH India supplies Jivolar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers.

Manufacturer / TM Owner

Medochemie Ltd.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Jivolar, a combination antidiabetic medication, is used to manage type 2 diabetes mellitus and related glycemic targets.

  • Type 2 diabetes mellitus: improves overall blood glucose control when combined with diet and exercise.
  • Inadequate control on metformin alone: adds DPP‑4 inhibition to achieve target HbA1c.
  • Adjunct to insulin therapy: helps reduce required insulin dose and stabilizes glycemic fluctuations.

How It Works

  • Metformin Hydrochloride activates AMP‑activated protein kinase, decreasing hepatic gluconeogenesis and increasing peripheral insulin sensitivity. Sitagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4, preventing degradation of incretin hormones (GLP‑1 and GIP), thereby enhancing glucose‑dependent insulin secretion and suppressing glucagon release. The combined actions lower fasting and post‑prandial glucose levels. These effects are additive, providing a broader glycemic control profile than either component alone.

Side Effects

Jivolar may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Nausea: mild gastrointestinal upset.
  • Diarrhea: loose stools.
  • Headache: mild tension‑type headache.

Serious or Rare Side Effects

  • Lactic acidosis: severe metabolic acidosis requiring urgent care.
  • Pancreatitis: abdominal pain with elevated pancreatic enzymes.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.

Precautions & Warnings

When prescribing Jivolar, clinicians should consider several precautionary measures to minimize risks.

  • Renal function: assess baseline creatinine clearance and monitor periodically.
  • Lactic acidosis risk: avoid in patients with severe renal impairment or hepatic disease.
  • Hypoglycemia risk: monitor closely when used with insulin or sulfonylureas.
  • Pregnancy: safety not established; use only if potential benefit justifies potential risk.
  • Vitamin B12 levels: monitor during long‑term metformin therapy as deficiency may develop.
  • Store at ambient temperature: keep in original container, protect from moisture and heat.

Avoid Interactions

Jivolar can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

  • Insulin or sulfonylureas: increased risk of hypoglycemia.
  • Iodinated contrast agents: may precipitate metformin‑associated lactic acidosis.
  • Cimetidine: can raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely)

  • Rifampin: may reduce sitagliptin exposure, decreasing effectiveness.
  • Diuretics: may affect glucose control and electrolyte balance.

Frequently Asked Questions

Jivolar is a prescription oral medication that combines metformin hydrochloride and sitagliptin. It is used to improve blood glucose control in adults with type 2 diabetes mellitus, typically as part of a comprehensive treatment plan that includes diet and exercise.

Metformin hydrochloride activates AMP‑activated protein kinase in the liver, which suppresses hepatic glucose production and enhances peripheral insulin sensitivity. This reduces fasting glucose levels and contributes to overall glycemic control.

Sitagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), preventing the breakdown of incretin hormones such as GLP‑1 and GIP. The increased incretin activity stimulates glucose‑dependent insulin secretion and reduces glucagon release, helping lower post‑prandial glucose.

The specific dose of Jivolar is determined by the prescribing healthcare professional based on individual patient factors such as renal function, current glycemic control, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of Jivolar in pregnancy and lactation has not been fully established. It should only be used if the potential benefits outweigh the risks, and the decision should be made by a qualified healthcare provider after a thorough assessment.

To request Jivolar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with metformin alone, Jivolar adds DPP‑4 inhibition, offering better post‑prandial glucose control without the weight gain associated with some sulfonylureas. Unlike insulin, it is administered orally and carries a lower risk of severe hypoglycemia when used alone.

Jivolar tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the medication out of reach of children and do not use after the expiry date.

Jivolar is taken orally, usually once daily with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically advised.

The most serious risks include lactic acidosis, which can be life‑threatening, and severe hypoglycemia when combined with insulin or sulfonylureas. Patients should be educated to recognize symptoms such as rapid breathing, abdominal pain, or confusion and seek immediate medical attention.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT